New Omicron BA.3.2 Variant Detected Across US, Experts Urge Vigilance Over Alarm
The BA.3.2 subvariant of the Omicron strain of Covid-19, characterized by dozens of new spike mutations, has been identified in 29 US states and Puerto Rico, according to the Centers for Disease Control and Prevention (CDC). However, infectious disease experts emphasize that there is currently no evidence to suggest it is more severe than other recent variants, calling for serious attention rather than alarm.
Expert Insights on BA.3.2's Characteristics and Risks
Dr Jake Scott, a Stanford professor and infectious disease expert who authored a systematic review of Covid vaccines for the New England Journal of Medicine, stated, "The right response to BA.3.2 is serious attention, not alarm." He highlighted that while the variant has substantial changes in its spike protein, the World Health Organization (WHO) has classified it as a "variant under monitoring" without assigning higher risk designations. WHO's vaccine composition group has flagged BA.3.2 for discussion at its May meeting, but Scott noted that it has not shown a sustained growth advantage over co-circulating variants, and no data indicate increased severity, hospitalizations, or deaths.
Current Impact and Public Health Recommendations
In the US, BA.3.2 accounts for a low percentage of overall analyzed Covid-19 infections, but in parts of Europe, it rose to a substantial share of sequenced cases without worse clinical outcomes. Marc Veldhoen, an immunologist at the University of Lisbon, explained that BA.3.2 is biologically similar to other Omicron subvariants, with symptoms akin to typical respiratory infections. He cautioned against media descriptions of it as "heavily mutated," noting that SARS-CoV-2 is nearly 30,000 base pairs long, making such terms relative.
Both experts agree that current vaccines appear effective against BA.3.2, maintaining protection against severe disease. Scott emphasized, "The question that actually matters is whether BA.3.2 meaningfully erodes protection against severe disease," and current evidence suggests it does not. He added that vaccines and prior infection build immune memory beyond antibodies, which remains durable across variants, helping to prevent hospitalizations and deaths.
Concerns and Context Regarding Pediatric Cases
One notable pattern is that BA.3.2 is overrepresented in pediatric samples in the Gisaid database, but Scott urged caution in interpreting this. He explained that sequencing data reflects testing and sequencing practices, not actual infection rates, as children with symptoms are more likely to be tested and sequenced than adults with mild infections. Alternatively, children may have less accumulated exposure to Covid-19 variants. Importantly, there is no signal of increased severity in children, and Scott advised against catastrophizing this pattern.
Broader Implications and Future Outlook
Public health officials, the general public, and doctors do not need to change their behavior in response to BA.3.2, according to Veldhoen. However, vaccine researchers should continue tracking the variant to inform future updates. WHO recommends masking and improved ventilation in high-risk environments to prevent all Covid-19 infections and related risks like long Covid. Scott concluded, "The goal was never to prevent every infection. It was to keep people out of the hospital. That protection has proven more robust than the variant-by-variant headlines often suggest."
